Pricing Log in Create free account
Friday 6 November 2026 Export RYTM’s income statement to Excel — free account

Rhythm Pharmaceuticals, Inc.

RYTM Healthcare Biotechnology

Rhythm Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $189.8 million, up 45.8% from fiscal 2024.

Revenue
+79.6%
EPS
+26.9%
Free cash flow
+95.4%

Quarter to September 2026, against a year earlier

112.38 7.36 +7.01%
Market cap
$7.3B
P/E
0.0×
Fwd P/E
−31.6×
Dividend yield
—
F-score
6/9
Altman Z
15.89
Beneish M
−2.93
Dividend safety
n/a
Overview Business Profile Earnings & Analysis
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios
Segments Valuation Filings

Rhythm Pharmaceuticals, Inc. 10-K filed Feb 26, 2026

Fiscal year 2025 · Period ended Dec 31, 2025 · Filed · accepted 5:02 PM ET · Document on sec.gov · Filing index

What changed

Item 1, Business Item 1A, Risk Factors Item 7, Management’s Discussion and Analysis

Item 1A, Risk Factors, against the 10-K filed Feb 28, 2025: 15 added · 18 removed · 146 modified; 4 with only figures updated; 2 moved without change